Literature DB >> 19868110

A REPORT ON THE SERUM TREATMENT OF TWENTY-SIX CASES OF EPIDEMIC POLIOMYELITIS.

H L Amoss1, A M Chesney.   

Abstract

1. Serum taken from recently recovered cases of poliomyelitis may be employed in its treatment and probably yields the best results. 2. When sterile for ordinary bacteria, free of corpuscles and hemoglobin, and when injected by the gravity method, observing well known rules of caution, it may be employed without danger. 3. The serum should be injected both intraspinally and intravenously, the latter either directly or by way of the subcutaneous tissues. 4. The earlier in the course of the disease the serum is employed in suitable doses, the more promise there is of benefit. 5. The action of the serum appears to be more precise and definite in arresting paralysis than in rapidly bringing about its retrogression. 6. The decision to employ the serum should rest upon a clinical examination supported by the results of the microscopic and chemical study of the cerebrospinal fluid. 7. The question of multiple and repeated injections of the serum has not yet been worked out. In the cases here reported and especially in the group in which no paralysis existed at the time of the first injection, the pathologic process either did not progress at all, or where there was extension, as in Cases 14 and 15, the upper segment of the spinal cord became rapidly involved, and was followed by respiratory paralysis and death. Probably in cases in which some degree of muscular weakness develops soon after the injection of serum, reinjection 12 to 24 hours later may be advantageous. The temperature curve may serve to indicate the time for reinjection. 8. The favorable results thus far achieved in human beings by means of the immune serum support and extend those obtained experimentally in monkeys and indicate, as was foreseen, that the milder or less fatal form of poliomyelitis appearing in man is even more amenable to the serum treatment than is the highly fatal disease produced by inoculation in monkeys.

Entities:  

Year:  1917        PMID: 19868110      PMCID: PMC2125499          DOI: 10.1084/jem.25.4.581

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  4 in total

1.  THE EFFECT OF INTRASPINOUS INJECTIONS OF SALVARSAN AND NEOSALVARSAN IN MONKEYS.

Authors:  A W Ellis; H F Swift
Journal:  J Exp Med       Date:  1913-10-01       Impact factor: 14.307

2.  EXPERIMENTAL EPIDEMIC POLIOMYELITIS IN MONKEYS.

Authors:  S Flexner; P A Lewis
Journal:  J Exp Med       Date:  1910-03-14       Impact factor: 14.307

3.  LOCALIZATION OF THE VIRUS AND PATHOGENESIS OF EPIDEMIC POLIOMYELITIS.

Authors:  S Flexner; H L Amoss
Journal:  J Exp Med       Date:  1914-09-01       Impact factor: 14.307

4.  THE RELATION TO THE BLOOD OF THE VIRUS OF EPIDEMIC POLIOMYELITIS.

Authors:  P F Clark; F R Fraser; H L Amoss
Journal:  J Exp Med       Date:  1914-03-01       Impact factor: 14.307

  4 in total
  8 in total

Review 1.  Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.

Authors:  Zhihong Zuo; Ting Wu; Liangyu Pan; Chenzhe Zuo; Yingchuo Hu; Xuan Luo; Liping Jiang; Zanxian Xia; Xiaojuan Xiao; Jing Liu; Mao Ye; Meichun Deng
Journal:  Front Pharmacol       Date:  2021-02-08       Impact factor: 5.810

2.  THE PASSAGE OF NEUTRALIZING SUBSTANCE FROM THE BLOOD INTO THE CEREBROSPINAL FLUID IN ACTIVELY IMMUNIZED MONKEYS.

Authors:  S Flexner; H L Amoss
Journal:  J Exp Med       Date:  1918-07-01       Impact factor: 14.307

Review 3.  Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates.

Authors:  Henu Kumar Verma; Batoul Farran; Lakkakula V K S Bhaskar
Journal:  Antib Ther       Date:  2020-05-27

Review 4.  A review of treatment modalities for Middle East Respiratory Syndrome.

Authors:  Yin Mo; Dale Fisher
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

5.  Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.

Authors:  Christine von Rhein; Tatjana Scholz; Lisa Henss; Romy Kronstein-Wiedemann; Tatjana Schwarz; Roman N Rodionov; Victor M Corman; Torsten Tonn; Barbara S Schnierle
Journal:  J Virol Methods       Date:  2020-12-01       Impact factor: 2.014

6.  THERAPEUTIC EXPERIMENTS WITH ROSENOW'S ANTIPOLIOMYELITIC SERUM.

Authors:  H L Amoss; F Eberson
Journal:  J Exp Med       Date:  1918-02-01       Impact factor: 14.307

7.  THE PASSAGE OF NEUTRALIZING SUBSTANCES FROM THE BLOOD INTO THE CEREBROSPINAL FLUID IN POLIOMYELITIS.

Authors:  S Flexner; H L Amoss
Journal:  J Exp Med       Date:  1917-04-01       Impact factor: 14.307

8.  EXPERIMENTAL STUDY OF A HORSE ANTIPOLIOMYELITIC SERUM.

Authors:  C P Rhoads
Journal:  J Exp Med       Date:  1931-01-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.